9 results on '"Verschelden, Gil"'
Search Results
2. Analysis of a Combined HBHA and ESAT-6-Interferon-γ-Release Assay for the Diagnosis of Tuberculous Lymphadenopathies
- Author
-
Mascart, Françoise, primary, Hites, Maya, additional, Watelet, Emmanuelle, additional, Verschelden, Gil, additional, Meuris, Christelle, additional, Doyen, Jean-Luc, additional, Van Praet, Anne, additional, Godefroid, Audrey, additional, Petit, Emmanuelle, additional, Singh, Mahavir, additional, Locht, Camille, additional, and Corbière, Véronique, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Presumed Urinary Tract Infection in Patients Admitted with COVID-19: Are We Treating Too Much?
- Author
-
Van Laethem, Johan, primary, Wuyts, Stephanie C. M., additional, Pierreux, Jan, additional, Seyler, Lucie, additional, Verschelden, Gil, additional, Depondt, Thibault, additional, Meuwissen, Annelies, additional, Lacor, Patrick, additional, Piérard, Denis, additional, and Allard, Sabine D., additional
- Published
- 2021
- Full Text
- View/download PDF
4. In Light of the SARS-CoV-2 Pandemic: Revisit of the Evidence Associating Zinc and Anti-viral Response
- Author
-
Noeparast, Amir, Verschelden, Gil, Degeyter, Deborah, Marco, Marco, Goyvaerts, Cleo, and Hites, Maya
- Subjects
medicine_pharmacology_other ,viruses - Abstract
Since the discovery of the first reported case with Zinc-deficiency in Iran1 by Prasad et al. in 1961, the knowledge on Zinc has increased significantly. Zinc is the second most abundant common trace mineral in the human body, responsible for vital biological functions from cell growth and development to cell homeostasis and immune response 2,3. Up to a fifth of the global population is estimated to suffer from different degrees of Zinc deficiency4. In the western world, Zinc deficiency is more prevalent among the geriatric population3, vegans/vegetarians, and people with certain underlying conditions4such as liver cirrhosis, inflammatory bowel disease, and various auto-immune disorders4,5. Zinc and Zinc deficiency has been associated with several infectious diseases 2,3. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is responsible for the ongoing pandemic belongs to the family of coronaviruses. SARS-CoV-2 has a high genetic similarity to another family member, SARS-CoV, which caused the first major epidemic of the 21st century6,7. Currently, there is no evidence linking the anti- SARS-CoV-2 response and the element Zinc. Herein and in light of the SARS-CoV-2 pandemic, we marshal the evidence associating the element Zinc with the anti-viral and antibacterial immune response as well as the cytokine storm and lung injury. Such a revisit of the precedent evidence may inspire further investigation assessing the relationship between Zincemia status and the anti-viral response in SARS-CoV-2 patients.
- Published
- 2020
5. Macrocytic anemia due to vitamin B12 deficiency: do not overlook coeliac disease
- Author
-
Meuwissen, Annelies Maurits Y, Verschelden, Gil, Sahebali, Shaira, Allard, Sabine, Mertens, Rembert, Lacor, Patrick, Internal Medicine, Faculty of Medicine and Pharmacy, Supporting clinical sciences, Pathology, Clinical sciences, and Microbiology and Infection Control
- Published
- 2019
6. Significant response to dabrafenib in a patient with Erdheim–Chester disease with BRAFV600E mutation
- Author
-
Verschelden, Gil, primary, Van Laethem, Johan, additional, Velkeniers, Brigitte, additional, Ilsen, Bart, additional, Noeparast, Amir, additional, and De Grève, Jacques, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
- Author
-
Noeparast, Amir, primary, Teugels, Erik, additional, Giron, Philippe, additional, Verschelden, Gil, additional, De Brakeleer, Sylvia, additional, Decoster, Lore, additional, and De Grève, Jacques, additional
- Published
- 2016
- Full Text
- View/download PDF
8. Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation: a case report and literature review.
- Author
-
Verschelden, Gil, Van Laethem, Johan, and De Grève, Jacques
- Published
- 2019
9. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
- Author
-
Benoit Misset, Hans Slabbynck, Ursula Smole, Linos Vandekerckhove, Nicolas Dauby, Helena Catharine Aegerter, Nicolas De Schryver, Jozefien Declercq, Catherine Legrand, Levi Hoste, Gil Verschelden, Fre Bauters, Xavier Wittebole, Bastiaan Maes, Eva Van Braeckel, Sébastien Anguille, Catherine Van Der Straeten, Marc Buyse, Sylvie Rottey, Tom Fivez, Dieter Stevens, Stefaan J. Vandecasteele, Maya Hites, Elke Govaerts, I Peene, Karel Van Damme, Simon Tavernier, Frank Hulstaert, Roos Colman, Stefanie De Buyser, Elisabeth De Leeuw, Jeroen Van der Hilst, Filip Moerman, Fabienne Liénart, Leen J M Seys, Leslie Naesens, Filomeen Haerynck, Ingel K. Demedts, Cedric Bosteels, Victor Bosteels, Pieter Depuydt, Johan Van Laethem, Bart N. Lambrecht, Internal Medicine, Supporting clinical sciences, Faculty of Medicine and Pharmacy, UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (SLuc) Service de soins intensifs, UCL - SSH/LIDAM/ISBA - Institut de Statistique, Biostatistique et Sciences Actuarielles, Van Laethem, Johan/0000-0002-2490-216X, Hoste, Levi/0000-0001-9733-1049, Naesens, Leslie/0000-0003-1715-0665, Declercq , Jozefien, Van Damme, Karel F. A., De Leeuw, Elisabeth, Maes, Bastiaan, Bosteels, Cedric, Tavernier, Simon J., De Buyser, Stefanie, Colman, Roos, Hites, Maya, Verschelden, Gil, Fivez, Tom, Moerman , Filip, Demedts, Ingel K., Dauby, Nicolas, De Schryver, Nicolas, Govaerts , Elke, Vandecasteele, Stefaan J., Van Laethem, Johan, Anguille, Sebastien, VAN DER HILST, Jeroen, Misset, Benoit, Slabbynck, Hans, Wittebole, Xavier, Lienart, Fabienne, LEGRAND, Catherine, BUYSE, Marc, Stevens, Dieter, Bauters, Fre, Seys, Leen J. M., Aegerter, Helena, Smole, Ursula, Bosteels, Victor, Hoste , Levi, Naesens, Leslie, Haerynck, Filomeen, Vandekerckhove, Linos, Depuydt, Pieter, van Braeckel, Eva, Rottey, Sylvie, Peene, Isabelle, Van Der Straeten, Catherine, Hulstaert, Frank, and Lambrecht, Bart N.
- Subjects
Male ,Pulmonary and Respiratory Medicine ,Population ,Antibodies, Monoclonal, Humanized ,law.invention ,Belgium ,Randomized controlled trial ,law ,Fraction of inspired oxygen ,medicine ,Humans ,Prospective Studies ,Hypoxia ,education ,Aged ,education.field_of_study ,Interleukin-6 ,SARS-CoV-2 ,business.industry ,Comment ,Hazard ratio ,COVID-19 ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,COVID-19 Drug Treatment ,Blockade ,Oxygen ,Cytokine release syndrome ,Treatment Outcome ,Respiratory failure ,Anesthesia ,Ferritins ,Female ,SOFA score ,Human medicine ,Cytokine Release Syndrome ,Respiratory Insufficiency ,business ,Interleukin-1 - Abstract
Background Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome. Methods We did a prospective, multicentre, open-label, randomised, controlled trial, in hospitalised patients with COVID-19, hypoxia, and signs of a cytokine release syndrome across 16 hospitals in Belgium. Eligible patients had a proven diagnosis of COVID-19 with symptoms between 6 and 16 days, a ratio of the partial pressure of oxygen to the fraction of inspired oxygen (PaO2:FiO(2)) of less than 350 mm Hg on room air or less than 280 mm Hg on supplemental oxygen, and signs of a cytokine release syndrome in their serum (either a single ferritin measurement of more than 2000 mu g/L and immediately requiring high flow oxygen or mechanical ventilation, or a ferritin concentration of more than 1000 mu g/L, which had been increasing over the previous 24 h, or lyrnphopenia below 800/mL with two of the following criteria: an increasing ferritin concentration of more than 700 mu g/L, an increasing lactate dehydrogenase concentration of more than 300 international units per L, an increasing C-reactive protein concentration of more than 70 mg/L, or an increasing D-dimers concentration of more than 1000 ng/mL). The COV-AID trial has a 2 x 2 factorial design to evaluate IL-1 blockade versus no IL-1 blockade and IL-6 blockade versus no IL-6 blockade. Patients were randomly assigned by means of permuted block randomisation with varying block size and stratification by centre. In a first randomisation, patients were assigned to receive subcutaneous anakinra once daily (100 mg) for 28 days or until discharge, or to receive no IL-1 blockade (1:2). In a second randomisation step, patients were allocated to receive a single dose of siltuximab (11 mg/kg) intravenously, or a single dose of tocilizumab (8 mg/kg) intravenously, or to receive no IL-6 blockade (1:1:1). The primary outcome was the time to clinical improvement, defined as time from randomisation to an increase of at least two points on a 6-category ordinal scale or to discharge from hospital alive. The primary and supportive efficacy endpoints were assessed in the intention-to-treat population. Safety was assessed in the safety population. This study is registered online with ClinicalTrials.gov (NCT04330638) and EudraCT (2020-001500-41) and is complete. Findings Between April 4, and Dec 6,2020,342 patients were randomly assigned to IL-1 blockade n=112) or no IL-1 blockade (n=230) and simultaneously randomly assigned to IL-6 blockade (n=227; 114 for tocilizumab and 113 for siltuximab) or no IL-6 blockade (n=115). Most patients were male (265 [77%] of 342), median age was 65 years (IQR 54-73), and median Systematic Organ Failure Assessment (SOFA) score at randomisation was 3 (2-4). All 342 patients were included in the primary intention-to-treat analysis. The estimated median time to clinical improvement was 12 days (95% CI 10-16) in the IL-1 blockade group versus 12 days (10-15) in the no IL-1 blockade group (hazard ratio [HR] 0.94 [95% CI 0.73-1.21]). For the IL-6 blockade group, the estimated median time to clinical improvement was 11 days (95% CI 10-16) versus 12 days (11-16) in the no IL-6 blockade group (HR 1.00[0-78-1-29]). 55 patients died during the study, but no evidence for differences in mortality between treatment groups was found. The incidence of serious adverse events and serious infections was similar across study groups. Interpretation Drugs targeting IL-1 or IL-6 did not shorten the time to clinical improvement in this sample of patients with COVID-19, hypoxic respiratory failure, low SOFA score, and low baseline mortality risk. Copyright (C) 2021 Elsevier Ltd. All rights reserved. Belgian Health Care Knowledge Center; VIB Grand Challenges program The authors acknowledge professional support and committed efforts from various organisations and individuals involved in this trial and thank all trial participants and clinicians involved in patient recruitment at the different participating sites. This study was funded by KCE, and KCE was involved in various aspects of the study design, management, and execution (Nelle Stocquart, Jillian Harrison). The VIB Grand Challenges Program (Sofie Bekaert) funded measurements of cytokines and the Ghent University Special Research Fund (BOF) supported the clinical follow-up of patients at Ghent University Hospital (UZ Ghent). The clinical trial team of the Department of Respiratory Medicine at UZ Ghent (Stefanie Vermeersch, Benedicte Demeyere, Anja Delporte) were involved in protocol development, amendment filing, and eCRF construction. The Health Innovation and Research Institute of UZ Ghent was involved in eCRF design, protocol design, ethical committee reporting, drug dispensing, trial monitoring, data cleaning, and sponsor site management (Charlotte Clauwaert, Dries Loncke, Hanife Kokur, Lieselot Van Landuyt, Joke Tommelein, Hélène De Naeyer). The hospital pharmacy of UZ Ghent dispensed drugs to all study sites (Els Kestens). Team members of the Primary Immune Deficiency laboratory (Karlien Claes, Veronique Debacker, Lisa Roels, Zara Declercq) handled samples from all study sites. The authors acknowledge the insights of the data safety monitoring board (Drs Renaat Peleman, Geert Leroux-Roels, Steven Callens, Frank Vermassen, Piet Hoebeke, Karim Vermaelen, A Dupont, Tomasz Burzykowski, and Marnik Vuylsteke under the chairmanship of SR).
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.